The Priority Review

Tag

COPD

3 stories

  1. Clinical trials

    Merck registers Phase 3 trial of ensifentrine for COPD exacerbation prevention

    Merck Sharp & Dohme LLC has registered a Phase 3, randomized, double-blind, placebo-controlled study (ENHANCE-3) to evaluate ensifentrine (MK-5884) for preventing moderate and severe COPD exacerbations. The trial plans to enroll 2136 participants, begin on October 23, 2026, and reach primary completion on April 29, 2029.

  2. Clinical trials

    Sanofi posts results of Phase 3 itepekimab trial in COPD

    The Phase 3 study, NCT04701983 (AERIFY-1), enrolled 1127 participants and completed primary data collection on April 11, 2025. Results were first posted on ClinicalTrials.gov on October 15, 2026.

  3. Clinical trials

    Sanofi posts results of Phase 3 Itepekimab trial in COPD

    The study, NCT04751487 (AERIFY-2), enrolled 1234 participants and completed in April 2025. It evaluated itepekimab versus placebo on exacerbation rates, pulmonary function, and safety in moderate-to-severe COPD patients.